If you landed here looking for Vioxx: Merck pulled the painkiller off the market worldwide on September 30, 2004, after a three-year study linked it to heart attacks and strokes. In November 2007 the company agreed to a $4.85 billion settlement program for heart attack and ischemic stroke claims that had already been filed or formally tolled by then. Merck reported finishing its payments into the settlement funds by the end of 2009, and that program is long closed. A brand-new Vioxx claim today would run into filing deadlines that expired many years ago.
The questions Vioxx raised haven’t gone away, though. Drugs and medical devices still get recalled, relabeled with new warnings, and pulled into large federal lawsuits. This guide explains how those injury claims work today: what counts as a defect, why it matters whether you took a brand-name or a generic drug, how mass litigation is organized, and the deadlines and fees involved.
What happened with Vioxx
Vioxx (rofecoxib) was approved for arthritis and acute pain. Merck withdrew it after data from a placebo-controlled trial called APPROVe, which was testing whether the drug prevented colon polyps, showed a higher rate of cardiovascular events in people taking it. Thousands of lawsuits followed, and the federal ones were consolidated before Judge Eldon Fallon in New Orleans as MDL No. 1657.
The 2007 deal split the money into two funds: $4.0 billion for heart attack claims and $850 million for ischemic stroke claims. It was open only to US residents whose injury happened in the United States, and only to people who already had a pending or tolled claim. Joining was voluntary, but the deal could be cancelled unless a large share of eligible claimants signed on. That structure, a private settlement program run alongside a federal MDL, is still the usual template for drug litigation.
Three ways a drug or device can be defective
Drug and device cases are a branch of product liability law, and they use the same three theories, with some twists.
Failure to warn is the most common. The claim is that the manufacturer knew, or should have known, about a risk and didn’t put an adequate warning on the label. With prescription products, most states say the warning goes to your doctor rather than to you, on the theory that the doctor is the one weighing risks and choosing the treatment. So the question often becomes whether a better label would have changed what your doctor prescribed or how you were monitored.
Design defect means the product itself is unreasonably dangerous even when made exactly as intended. These claims are easier to picture with devices, like an implant made from a material that breaks down in the body, than with drugs.
Manufacturing defect means something went wrong in production: a contaminated batch, the wrong dose in a tablet, a device that left the factory with a flaw the design didn’t call for. You don’t have to show the company was careless, only that your unit departed from its own specifications and that caused your injury. Lot numbers matter a great deal here.
Every one of these also requires proof that the product caused your injury. That usually means medical experts, and it is where many drug cases are won or lost. Showing that a drug can cause a condition in general is a separate fight from showing it caused yours.
Brand-name or generic: why it changes everything
Four Supreme Court decisions shape who can be sued for a drug or device, and the dividing lines are not intuitive.
Start with brand-name drugs. In Wyeth v. Levine (2009), a musician lost her arm to gangrene after an anti-nausea drug was injected the wrong way, and she sued the brand maker for an inadequate warning. The company argued that because the FDA had approved its label, state law couldn’t second-guess it. The Court disagreed. A federal rule known as the “changes being effected” regulation lets a brand manufacturer strengthen a warning on its own and then tell the FDA, so the company could have complied with both state and federal law. Brand-name failure-to-warn claims generally survive.
Generic drugs came out the other way. In PLIVA v. Mensing (2011), the Court held that federal law requires a generic label to match the brand’s label, so a generic maker can’t change its warning on its own, and state failure-to-warn claims against it are preempted. Two years later, Mutual Pharmaceutical v. Bartlett (2013) extended that to design defect claims against generic makers, rejecting the argument that the company could simply stop selling the drug.
The practical result is harsh. Two people can take the same molecule, suffer the same injury from the same missing warning, and one has a claim while the other may not, depending on which bottle the pharmacy handed over. Given how often pharmacies fill prescriptions with generics, that rule shuts out a lot of people.
A few states have tried to close the gap. In T.H. v. Novartis (2017), the California Supreme Court held that a brand-name company can owe a duty of care to people injured by the generic version, because the generic label is a copy of the brand label the brand company controls. The court said that duty can continue even after the brand company sells off the drug. It also acknowledged that only a handful of courts elsewhere have taken that view. Most states don’t allow it, so whether you have any defendant at all can depend on where you live.
Ask your pharmacy for a printout of your prescription history, including the manufacturer (labeler) for each fill. Keep any bottles, packaging and leftover pills. Whether you took the brand or a generic, and whose generic, can decide a case before anyone looks at the medical evidence.
Medical devices: how the device was approved matters
Devices have their own preemption rule, written into the Medical Device Amendments of 1976, and it turns on the FDA pathway the device went through.
The highest-risk devices (many heart devices, some implants) go through premarket approval, or PMA, a detailed FDA review of that specific design. In Riegel v. Medtronic (2008), the Court held 8 to 1 that state claims challenging the safety or labeling of a PMA device are expressly preempted. What’s left is a narrow lane: a “parallel” claim that the company violated the FDA’s own requirements, for example by making the device differently from what the FDA approved.
Most devices instead reach the market through the 510(k) process, which clears a device because it’s “substantially equivalent” to one already sold. The Court held back in 1996, in Medtronic v. Lohr, that 510(k) clearance doesn’t block ordinary state injury claims. That’s a big reason so many device lawsuits can go forward at all. Your lawyer will look up the device’s FDA history early, because it can make or break the case.
Recalls, safety warnings and reporting a problem
Most recalls are carried out by the company itself, with the FDA classifying them. Class I is the most serious, meaning there’s a reasonable probability the product will cause serious health problems or death. Class II covers products that may cause temporary or medically reversible problems, or where serious harm is unlikely. Class III recalls involve products unlikely to cause any harm, such as a labeling error. The FDA posts recalls and safety alerts on its website, along with drug safety communications when it adds a warning or changes how a drug should be used.
A recall can help a case, since it’s an admission that something was wrong with at least some units. It is not proof that the product caused your particular injury, and many lawsuits involve products that were never recalled at all.
Anyone can report a bad reaction or device problem to the FDA through MedWatch, either online or on Form 3500B, the version written for patients and consumers. Manufacturers, by contrast, are legally required to report adverse events they learn about. A report won’t get you compensation, but it puts the event on record.
Don’t stop taking a prescribed drug, or ask to have a device removed, because of an ad or a news story without talking to your doctor first. Stopping some medications abruptly is dangerous, and a removed device needs to be preserved properly if there’s ever a claim. Ask the hospital in writing to keep any explanted device.
MDLs, mass torts and class actions
When many people file similar suits in federal courts around the country, the Judicial Panel on Multidistrict Litigation (JPML) can send them all to one judge for pretrial work under 28 U.S.C. § 1407. This is a multidistrict litigation, or MDL. It isn’t the same as a class action, and people often confuse the two.
| MDL (mass tort) | Class action | |
|---|---|---|
| Your case | You file your own lawsuit and keep it | A representative sues on behalf of everyone in the class |
| Who decides to settle | You, through your own lawyer | The court approves a deal for the whole class; you may be able to opt out |
| What you get | Depends on your own injuries and evidence | Usually a share set by a formula |
| Typical use | Personal injury from drugs and devices | Economic losses, like overpaying for a product |
Personal injury claims rarely work as class actions, because every person’s medical history and injury is different. In an MDL, the judge manages shared discovery and expert fights, then often sets a few “bellwether” trials to test how juries react. Many MDLs end in a global settlement program like the Vioxx one, where each claimant decides whether to join. Others shrink after the judge throws out the plaintiffs’ experts. If a case doesn’t settle, it can be sent back to the court where it was filed for trial.
The JPML publishes a monthly list of pending MDLs. Its August 3, 2026 report included drug and device dockets for Depo-Provera (MDL 3140, Northern District of Florida), GLP-1 receptor agonists such as semaglutide drugs (MDL 3094, Eastern District of Pennsylvania), Suboxone film (MDL 3092, Northern District of Ohio), Paragard IUDs (MDL 2974, Northern District of Georgia) and Bard implanted port catheters (MDL 3081, District of Arizona). An MDL’s existence means a court found the cases shared enough common questions to coordinate. It says nothing about whether the claims will succeed.
How long you have to file
Each state sets its own deadline, and drug cases add a complication: the injury may not be linked to the drug until years later, often when a new warning comes out. Many states start the clock when you knew, or reasonably should have known, that the product may have caused your injury, rather than when you took it. Others are stricter. On top of the regular deadline, some states have an outer limit, called a statute of repose, that cuts off claims a fixed number of years after the product was sold no matter when you found out.
- Tennessee: product claims must be filed within the general injury deadline, and also within 10 years of the product’s first purchase (or 1 year after its expected useful life, if shorter). The repose period doesn’t apply to asbestos claims, and silicone breast implants have their own 25-year rule.
- Texas: product suits generally must be brought within 15 years of the sale, but there’s an exception for diseases caused by exposure inside that window whose symptoms didn’t show up until later.
- Vaccines: most routine vaccine injuries go through the National Vaccine Injury Compensation Program at the US Court of Federal Claims, not a regular lawsuit. Injury claims must be filed within 3 years of the first symptom, and death claims within 2 years of the death.
Joining an MDL doesn’t pause your deadline. You still have to file a lawsuit in time, or sign a written tolling agreement with the manufacturer, which some MDLs allow.
Deadlines in drug cases often start when you learn of a possible link, which can be the day a new FDA warning or recall is announced. If you suspect a drug or device hurt you, talk to a lawyer soon rather than waiting to see how a mass tort plays out.
What drug injury lawyers charge
These cases are handled almost entirely on contingency: the lawyer takes a percentage of any recovery and nothing if you lose. Around a third is common, some agreements go higher if the case is litigated for years, and the agreement has to be in writing under the ethics rules most states follow, spelling out the percentage and how case expenses are handled. Expenses can be large in drug litigation because of expert witnesses.
MDLs add a layer. The court usually appoints a committee of plaintiffs’ lawyers to do the shared work, and it often orders a “common benefit” assessment, a percentage taken from each settlement to pay for that work. Ask whether that comes out of the lawyer’s fee or out of your share.
Ask, too, who will actually handle your case. Many TV and online ads are run by marketing firms or by lawyers who refer most cases elsewhere. Under the ABA’s model rules, two firms can split a fee only if you agree in writing, including to each firm’s share, and either the split tracks the work each does or both firms take responsibility for the case. So you have a right to know who is involved. If you don’t have a name to start with, your state bar’s lawyer referral service can point you to someone, and the ABA keeps a directory of those services. If a doctor’s prescribing decision is the real problem rather than the drug itself, that’s a medical malpractice question, and our personal injury guide covers how injury claims settle and how fees come out of a recovery.
Sources
- Merck & Co. Form 10-K for 2007 (Vioxx withdrawal and settlement agreement)
- Merck Sharp & Dohme Form 10-K for 2009 (settlement payment status)
- US District Court, E.D. La.: In re Vioxx Products Liability Litigation, MDL 1657, findings of fact (2010)
- Congressional Research Service: Preemption of Drug and Medical Device Claims (R43218)
- Wyeth v. Levine, 555 U.S. 555 (2009)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
- Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013)
- Riegel v. Medtronic, Inc., 552 U.S. 312 (2008)
- T.H. v. Novartis Pharmaceuticals Corp., Cal. Supreme Court No. S233898 (2017)
- 21 C.F.R. § 7.3: recall definitions and classes
- FDA: MedWatch forms for safety reporting
- 28 U.S.C. § 1407: Multidistrict litigation
- JPML: Pending MDL dockets by actions pending, August 3, 2026
- Tenn. Code § 29-28-103
- Tex. Civ. Prac. & Rem. Code § 16.012
- HRSA: National Vaccine Injury Compensation Program brochure (archived)
- ABA Model Rule 1.5: Fees
- ABA Lawyer Referral Directory